All Posts By

Laboratory Services

Compliance & Safety, General Information, Referral/Sendouts

Weather Impact on Send Out Testing

We want to inform you about an important update regarding T-Spot test collections and deliveries. Due to severe weather conditions expected to affect parts of the United States, we have been advised by our reference laboratory to suspend the collection and sending of this test on Monday, February 17 after 3 p.m. through Tuesday, February 18. Testing collection will begin again on Wednesday, February 19th, unless the request is extended.

This precaution is necessary to ensure the safety and integrity of the specimens, as well as to avoid any potential delays or issues that could arise from the adverse weather. We appreciate your understanding and cooperation during this time.

General Information

Reminders: COVID Collection

Corewell Health Laboratories no longer offers Covid collection observations or collections at any of our draw sites/laboratories.

If your patient is experiencing symptoms and requires a Covid test, please choose one of the options below:

Collect the specimen in your office and send the specimen to any Corewell Health Laboratory or with your Corewell Health Courier, if available.

• Please be sure to place a collected order in Epic or your EMR, or include a paper order with the specimen.

• Please make sure the specimen is labeled with 2 patient identifiers, date and time of collection, and source (nasopharyngeal or nares)

For all other options please visit: Corewell Health COVID-19 screening and testing

NOTE: Walk-in COVID-19 testing is not available at any of our sites, including emergency departments, urgent care locations or walk-in clinics. Testing is available to registered patients who are seeking medical treatment.

Advanced Technology Laboratory

Human Papillomavirus (HPV) Testing Update

Corewell Health South and Corewell Health West Laboratories 

Effective Date: February 3, 2025 

Human Papillomavirus (HPV) Genotypic testing will be updated to expand acceptable sources and collection methods. The following two HPV tests will be available, and the corresponding testing algorithm will be driven by the clinician specified specimen source and collection method/device.  

New Test: Self-Collect HPV High-Risk Screen with HPV Genotype Reflex (LAB1231853)  

  • Testing Restricted to HPV only –Co-testing Not Available: PAP or STI (CT, NG, TV)  
  • Detection of 14 HR HPV genotypes:  
    • HPV Genotype 16  
    • HPV Genotype 18
    • Other HR  HPV – includes 31,33,35,39,45,51,52,56,58,59,66,68  
  • Collection Information:  
    • Acceptable Source: Patient Self-collected vaginal  
    • Collection Device: Rovers® Evalyn® Brush  (ITM-1303902)
    • Collection Instructions: Patients must use the Evalyn Brush in a healthcare setting (i.e. physician office or clinic) to self-collect a vaginal specimen following the Evalyn Brush collection instructions. (Spanish instructions) 
    • A trained healthcare staff member must immediately suspend the Evalyn Brush into a vial of ThinPrep PreservCyt solution following transport instructions. The ThinPrep PreservCyt vial can then be transported to the lab at 2 to 30°C.  
    • This may not be collected at home or in an outpatient draw site. 

Corewell Health Southwest: Effective February 3, 2025, PAP and HPV results will once again be bundled for all orders placed from that date onward. 

Continue Reading

Advanced Technology Laboratory, General Information

Chromosome Analysis Update

Chromosome Analysis Prenatal and Chromosome Analysis Prenatal Limited orders will now include cryopreservation of prenatal specimens (amniotic fluid and chorionic villi), excluding those found to have straightforward abnormalities (i.e. whole chromosome copy gain).

 

TEST INFORMATION

  • Array Comparative Genomic Hybridization (ACGH), Direct Prenatal with Limited Chromosome Analysis LAB1231125
  • Chromosome Analysis, Prenatal TEST LAB2111376
Chemistry, General Information

Discontinuation of CKMB

Effective Wednesday, January 1, 2025, the in-house test, Research Creatine Kinase MB Fraction (CK-MB) (LAB2111534) will be made inactive. Recommended alternative testing is CK-MB (CK-2) (TC:17581) which is referred to Quest Diagnostics.

For questions or additional information, please use the Contact Us link above.

Referral/Sendouts

Weather Impact on Send Out Testing

We want to inform you about an important update regarding T-Spot, ImmuKnow, and CMV T-Cell Immunity Panel, test collections and deliveries. Due to severe weather conditions expected to affect parts of the United States later this week, we have been advised by our reference laboratory to suspend the collection and sending of these three tests on Thursday, January 9, and Friday, January 10. Testing collection will begin again on Monday, January 13th.

This precaution is necessary to ensure the safety and integrity of the specimens, as well as to avoid any potential delays or issues that could arise from the adverse weather. We appreciate your understanding and cooperation during this time.

Compliance & Safety, Education & Training, General Information

Updated Advanced Beneficiary (ABN) Statuses (Corewell Health Epic Users)

On Tuesday, Jan. 7, you will see changes to the ABN Status list in Epic, making it easier to select the appropriate status from available options.

In an effort to optimize workflows, the ABN statuses in Epic have been changed to be more efficient. Some statuses have been removed based on volume of use and feedback from clinicians. Other options have been changed to ensure clarity after review by Informatics, Compliance, and Revenue Cycle. The information below lists the new options and when to use them. Please refer to Epic Proportions for more information.

Attention providers: to reduce your ABN workflow burden, please select one of the first two Provider ABN statuses at the time of order entry only. The collection of signed ABN waivers will occur later by office, laboratory, or imaging staff using the three ABN Signed statuses when the specimen is being collected or when the imaging procedure is being performed. If your office routinely collects laboratory specimens, please instruct your staff to collect ABN signature waiver at the time of specimen collection.

Status Options Available after January 7, 2025:

  • Provider: ABN Discussed. Await Signature. [205] = Providers placing orders when the patient is present to discuss ABN, select this option. This allows the provider to place the order while also allowing lab or radiology staff the ability to complete their process as usual later and avoid the need for a new order. Patient will sign during lab/imaging procedure.
  • Provider: ABN Not Discussed. Patient Not Present. [206] = Providers placing orders when the patient is not available or present, select this option. This allows the provider to place the order while also allowing lab or radiology staff the ability to complete their process as usual later and avoid the need for a new order. Lab/imaging will need to discuss ABN and sign.
  • ABN Signed, Service Accepted (Option 1 – Bill Medicare) [3] = This status indicates that a patient has signed the form, wants to receive the service, and agrees to be financially responsible for the service if Medicare does not pay. This option should only be used by the person who is presenting the ABN to the patient for signature.
  • ABN Signed, Service Accepted (Option 2 – Do not Bill Medicare) [9] = This status indicates that a patient has signed the form, wants to receive the service, agrees to be financially responsible for the service, and agrees not to bill Medicare. This option should only be used by the person who is presenting the ABN to the patient for signature.
  • ABN Signed, Service Declined [6] = This status indicates that a patient has signed the form and does not want to receive the service. Typically, the clinician cancels the order in this situation. If a patient signs the form and declines the service but the physician believes it is important to proceed with the service at Corewell Health’ expense the test should not be canceled.
  • Notice Printed [2] = This status is automatically assigned to an ABN when the ABN is printed. In practice, “ABN Printed” can function as either an initial or intermediate status, because staff can print a copy of the ABN before or after presenting the form to the patient.
  • Notice Triggered [1] = This status is automatically assigned to new ABN forms. Indicates an ABN warning has been prompted. The order/procedure will NOT be able to be signed when the ABN is in this state.
General Information

Update in Beta CTX-1 (Cross Laps) Testing

Effective January 8, 2025, a new version of Beta CTX-1 (Cross Laps) will be implemented with the discontinuation of the previous version.

The analytical measuring range and reference ranges will be updated with the new version of the test. It is recommended to not directly compare the results between the new and old version of the test. If assistance is needed to aid in trending results between the new and old version of the test, please use the contact us link above or contact the Corewell Health Reference Laboratory West, Immunochemistry Department.

TEST INFORMATION

Discontinue: Beta CTX-1 (Cross Laps) LAB3656, Interface Code 55122
NEW: Beta CTX-1 (Cross Laps) LAB1231780, Interface Code 1231780
General Information, Microbiology

Influenza Antigen Testing (December 2024)

Influenza prevalence fluctuates seasonally, and case numbers are currently increasing throughout West Michigan. The onset of “flu season” varies year-to-year though typically begins its upswing in the month of December. It is important for providers to have an awareness of influenza prevalence (in addition to other respiratory viruses) to help guide when influenza testing should be pursued.

The use of point of care (POC) antigen testing reduces both the cost to the patient and turn-around-time as compared to lab-based molecular methods. POC antigen tests are typically available for COVID-19, influenza A/B, and as a COVID-19/influenza A/B combination test. During warmer months when influenza prevalence is negligible yet COVID-19 may be circulating, a COVID-only antigen test may be helpful for diagnosis. As influenza increases into colder months, a COVID-19/Influenza A/B combo test would act as a screen for both viruses.

POC tests generally have high analytical specificity but lack the sensitivity of nucleic acid amplification methods (e.g. PCR). For this reason, PCR testing is still recommended for hospitalized patients and for outpatients with a negative POC result if influenza is still suspected and if the result will impact clinical decision making. Influenza PCR may be ordered as a standalone test (LAB3255) or as a part of a panel alongside COVID-19 and RSV (LAB1230746).

 

Test Information

  • Influenza PCR Epic Code: LAB3255, Interface EMR Code: 11594, CPT Code 87502
  • COVID-19, Influenza A/B, RSV PCR Epic Code: LAB1230746, Interface EMR Code: 1230746, CPT: 0241U

 

Contact/Resources

Local Infection Prevention Team

Michigan Department of Health and Human Services